725
Views
12
CrossRef citations to date
0
Altmetric
Commentary

Pneumococcal conjugate vaccines for adults

Reasons for optimism and for caution

&
Pages 1334-1336 | Received 11 Apr 2014, Accepted 22 Apr 2014, Published online: 24 Apr 2014
 

10.4161/hv.28962

Disclosure of Potential Conflicts of Interest

D.M.W. has received consulting fees from Merck (the manufacturer of PPV23) and receives salary support from an investigator-initiated research grant from Pfizer (the manufacturer of PCV13) to Yale University. E.D.S. has nothing to disclose.

Acknowledgments

This publication was made possible, in part, by support from CTSA Grants Number UL1 TR000142 and KL2 TR000140 from the National Center for Research Resources (NCRR) and the National Center for Advancing Translational Science (NCATS), components of the National Institutes of Health (NIH), and NIH roadmap for Medical Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NIH.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.